Brief: Simcere Pharma Withdraws NDA For Rademikibart, Expects To Resubmit Within April 2026
22/04/2026 16:22
April 22 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK: PHARMA WITHDRAWS NDA FOR RADEMIKIBART, EXPECTS TO RESUBMIT WITHIN APRIL 2026 TO SEEK REGULATORY APPROVAL FOR RADEMIKIBART MARKET LAUNCH Further company coverage: 2096.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Receives Clinical Trial Approval For SIM0689 From China's NMPA
Brief: Simcere Pharmaceutical Enters Exclusive Promotion Service Agreement With Primegenx Therapeutics
Brief: Simcere Pharmaceutical Receives NMPA China Clinical Trial Approval For SIM0613
Brief: Simcere Pharmaceutical Says NDA For Rademikibart Accepted By NMPA
Brief: Simcere Pharma Withdraws NDA For Rademikibart, Expects To Resubmit Within April 2026